Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
U.S. Food and Drug Administration Commissioner Robert Califf defended the agency's role in addressing the country's obesity ...
Denmarks economic prospects are surging, with the government revising GDP growth forecasts upwards for 2024 and 2025, largely ...
The weight loss revolution is in full swing, with the number of patients receiving Wegovy (NVO) having doubled while those ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Brooks admitted that when she was taking Ozempic she 'lost a little bit of the motivation and the strength to work out.' ...
In a study trial, Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in weight loss efficacy. The study was conducted by ...
Eli Lilly and Company LLY announced that its popular obesity drug, Zepbound (tirzepatide) demonstrated more weight loss than ...
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from ...